交易中 10-06 11:18:14 美东时间
-0.150
-0.58%
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
09-26 02:00
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
09-26 01:56
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
09-22 22:40
These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
09-15 03:46
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
07-09 01:29
Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.
06-29 22:35
Beam Therapeutics (NASDAQ:BEAM) just disclosed its Q4 earnings on Tuesday, Febr...
02-24 20:08
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
01-01 06:06
由“木头姐”伍德管理的ARK创新ETF(ARKK.US)今年以来表现亮眼,但近期资金流向显示投资者可能在获利了结。 据报道,截至上周末,该科技股重仓ETF出现27亿美元资金流出,为至少一年以来最大规模。ARK Invest尚未就此发表评论。该基金当前总资产规模约为130亿美元。 不过,资金面并非单一方向。数据显示,上周ARKK同时录得约28亿美元净流入,为2021年以来单周最高水平,创下历史新高。分析人士指出,在大规模资金涌入后出现部分赎回属正常现象,但若赎回规模持续扩大,可能迫使基金抛售持股。 目前,ARKK的前几大重仓股包括特斯拉(TSLA.US)、Roku Inc(ROKU.US)、Co...
2025-08-20 06:00